On August 18th, we recognize World Breast Cancer Research Day, celebrating the groundbreaking research that has revolutionized breast cancer treatment and fuels hope for a future without this disease.
𝗖𝘂𝗿𝗿𝗲𝗻𝘁 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲
Breast cancer remains the most common cancer among women globally, accounting for 31% of female cancers and the second leading cause of cancer-related deaths. While early detection and improved treatments have boosted survival rates, challenges persist. About two-thirds of breast cancers are endocrine-sensitive (HR+/HER2-), yet up to 20% of these cases relapse within 10 years, highlighting the need for ongoing research and new therapies.
𝗖𝗗𝗞𝟰/𝟲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀: 𝗔 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗚𝗮𝗺𝗲-𝗖𝗵𝗮𝗻𝗴𝗲𝗿
The development of CDK4/6 inhibitors has been a major breakthrough in breast cancer treatment. When combined with endocrine therapy, these inhibitors have significantly improved progression-free survival, overall survival, and quality of life in HR+/HER2- advanced breast cancer. Current research is exploring their use in early-stage breast cancer, including in neoadjuvant (pre-surgical) and adjuvant (post-surgical) settings.
𝗖𝗗𝗞𝟰/𝟲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗶𝗻 𝗘𝗮𝗿𝗹𝘆 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿
The use of CDK4/6 inhibitors in early breast cancer is gaining interest. Ongoing research aims to identify which patients will benefit most and to establish optimal treatment durations, with genomic platforms also being investigated for predicting success.
𝗠𝗶𝘅𝗲𝗱 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 𝗶𝗻 𝗔𝗱𝗷𝘂𝘃𝗮𝗻𝘁 𝗧𝗵𝗲𝗿𝗮𝗽𝘆
Several large trials have evaluated CDK4/6 inhibitors in early breast cancer with mixed results. PALLAS and PENELOPE-B found no significant benefit from adding palbociclib to standard therapy, while MONARCH-E showed that abemaciclib reduced recurrence risk. These outcomes highlight the complexity of breast cancer treatment and the need for further research.
𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗮𝗻𝗱 𝗙𝘂𝘁𝘂𝗿𝗲 𝗗𝗶𝗿𝗲𝗰𝘁𝗶𝗼𝗻𝘀
Key challenges include identifying reliable biomarkers to predict who will benefit from CDK4/6 inhibitors, understanding resistance mechanisms, and ensuring patient adherence to treatment. Personalized treatment strategies for advanced breast cancer are crucial, with ongoing research into optimal drug combinations and the potential for rechallenging with alternative CDK4/6 inhibitors in endocrine-resistant cases.
𝗔 𝗖𝗼𝗺𝗺𝗶𝘁𝗺𝗲𝗻𝘁 𝘁𝗼 𝗮 𝗖𝗮𝗻𝗰𝗲𝗿-𝗙𝗿𝗲𝗲 𝗙𝘂𝘁𝘂𝗿𝗲
World Breast Cancer Research Day highlights the progress made in treating breast cancer and the ongoing need for research and innovation, aiming for a future where breast cancer is no longer a threat to women's lives worldwide.
Read more:
#WorldBreastCancerResearchDay #BreastCancerResearch #EndBreastCancer #BreastCancerAwareness #Integremed
